4 results
To determine the within and between variability of pharmacokinetic (PK) profiles in patients treated with DOACs in daily practice
To measure DOAC levels just before surgery of all DOAC patients in the LUMC with elective surgery for which ceasing of DOAC treatment is required.
1) To evaluate the efficacy and safety of the standard clinical care at the AMC in this patient population by the clinical outcomes (recurrent) thrombotic events and bleeding complications respectively.2) To evaluate the change in quality of life in…
PART B (FL phase IIb *PARADIGME*):Primary objective:Randomised section of Part B- To evaluate the efficacy of the *40/15* dose regimen (40 mg lilotomab / 15 MBq/kg Betalutin) compared with *100/20* dose regimen (100 mg/m2 lilotomab/ 20 MBq/kg…